Novel Coronavirus Pneumonia
Conditions
Keywords
mild, common
Brief summary
This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.
Detailed description
The purpose of this study was to evaluate the efficacy and safety of Tanreqing capsule in the treatment of mild and common COVID-19. The trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial design. A total of 480 patients were divided into 2 groups: experimental group and control group 3:1. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.
Interventions
DRUGTanreqing capsule
3 capsules per time, 3 times a day
DRUGTanreqing capsule simulator
3 capsules per time, 3 times a day
Sponsors
Ruijin Hospital
Jiangsu Famous Medical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. According to the Diagnosis and Treatment Plan for Pneumonia Infected by novel coronavirus (Trial Version 9), those who are in line with the diagnosis of novel coronavirus pneumonia and whose clinical classification is light and ordinary； 2. Aged greater than 18, with no gender limitation; 3. Symptom score greater than or equal 3 points; 4. Voluntarily accept the drug treatment and sign the informed consent.
Exclusion criteria
1. Patients with severe primary respiratory diseases or other pathogenic microbial pneumonia that needs to be differentiated from COVID-19; 2. immune deficiency disease, or use of immunosuppressants or glucocorticoids in the last 3 months; 3. pregnant and lactating women; 4. People with allergic constitution (allergic to more than two drugs or food or known allergic to the drug used in this study); 5. mentally ill persons or persons without self-awareness; 6. Patients whose expected survival time from screening is not more than 48 hours; (7) those who have been intubated or mechanically ventilated at the time of screening; (8) In patients with serious primary diseases of heart, brain, liver and kidney, ALT and AST were 1.5 times higher than the upper limit of normal value; (9) Other conditions that the investigator considers inappropriate for clinical trial participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time from the first dose to sustained clinical recovery | 8 days | Symptom domains and minors disappear completely within 7 days treatment period after randomization, and maintain it for 2 days without recurrence and the disease don't aggravate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Novel coronavirus N and ORF gene changes | 8 days | Nucleic acid detection was performed on the 0, 1, 2, 3, 4, 5, 6 and 7 days respectively. The fluorescent quantitative PCR method was used to determine the Ct value of N gene and ORF gene in novel coronavirus nucleic acid detection. Negative: no Ct value or Ct value\>40. Positive: Ct value\<35. Ct value (cycle threshold) refers to the Ct value of nucleic acid detection, that is, the number of cycles required when the pcr fluorescence signal reaches the threshold. |
| The time from the first dose/first testing positive of virus to testing sustained negative of virus within 7 days treatment period after randomization | 8 days | Testing sustained negative of virus was defined two consecutive (at least 24 hours apart) nasal swabs with new coronavirus nucleic acid detection CT values 35 ,and the negative event date was defined by first negative occurrence. |
| Effective rate of wind heat attacking lung syndrome | 8 days | The time from the first dose to sustained clinical improvement defined total scores for symptom domains and minors was \<3 within 7 days treatment period after randomization. |
| Duration of disappearance of main symptoms of wind heat attacking lung syndrome | 8 days | The time from the first dose to sustained complete disappearance within 7 days treatment period after randomization for every symptom domain, and these two outcomes definition were similar to the primary outcome. |
| Weight conversion rate (ratio of light type to ordinary type and ordinary type to heavy type) | 90 days | Proportion of patient experiencing progression to severe illness diagnosed by Trial draft version 9 of Diagnosis and Treatment Protocol for novel Coronavirus pneumonia within 7 days treatment period after randomization, during period from the end of 7 days treatment period to discharged from hospital and 3-month follow-up period after discharge. |
Countries
China
Outcome results
None listed